Radium-223 Dichloride Approved for Patients with Castration-resistant Prostate Cancer


Get Permission

On May 15, 2013, the U.S. Food and Drug Administration approved radium Ra 223 dichloride (Xofigo) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease.  Radium-223 dichloride is an alpha-particle–emitting radiotherapeutic drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover, such as bone metastases.

Study Details

The approval was based on a double-blind, randomized, placebo-controlled trial in patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease. Patients were allocated 2:1 to radium-223 dichloride at 50 kBq/kg (1.35 microcurie/kg) intravenously every 4 weeks for six cycles plus best standard of care (n = 541) or to matching placebo plus best standard of care (n = 268). Best standard of care included local radiotherapy, corticosteroids, antiandrogens, estrogens, estramustine, or ketoconazole.  All patients were to continue androgen deprivation therapy. The median age was 71 years, 94% were Caucasian, 86% had an ECOG performance status of 0-1, and 58% had received prior docetaxel. Fifty-four percent of patients used opiate and 44% used nonopiate pain medications.  Overall survival was the primary endpoint.

At the prespecified interim analysis, a statistically significant improvement in overall survival was demonstrated (HR = 0.70, 95% CI = 0.55–0.88; P = .00185).  The median overall survival was 14.0 and 11.2 months in the radium-223 dichloride and placebo arms, respectively. The improvement in overall survival was supported by a delay in time to first symptomatic skeletal event favoring the radium-223 arm.

Side Effects

The most common (≥ 10%) adverse reactions in patients receiving radium-223 dichloride were nausea, diarrhea, vomiting, and peripheral edema. The most common hematologic laboratory abnormalities were anemia, lymphocytopenia, leukopenia, thrombocytopenia, and neutropenia. Two percent of patients on the radium-223 arm experienced bone marrow failure or ongoing pancytopenia. No patients on the placebo arm experienced bone marrow failure or pancytopenia.

The recommended dose and schedule for radium-223 is 50 kBq/kg (1.35 microcuries/kg) administered by slow intravenous injection over 1 minute every 4 weeks for 6 doses. ■


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.